Article

CMS expands coverage for OPT with verteporfin

Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
Related Content
Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform
April 13th 2025

Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform

Commercial real estate and your practice, part two with Colin Carr
May 21st 2022

Commercial real estate and your practice, part two with Colin Carr

How COVID-19 shifted ophthalmologist-patient communication
March 21st 2025

How COVID-19 shifted ophthalmologist-patient communication

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
May 12th 2022

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Physicians can use media training, public relations to combat medical misinformation
July 29th 2024

Physicians can use media training, public relations to combat medical misinformation

Mental health and ophthalmology
May 17th 2024

Mental health and ophthalmology

© 2025 MJH Life Sciences

All rights reserved.